Videos

REVIEW UroToday

RadiCal Trial TT

Search

The RadiCaL Study: Enhancing Cabozantinib with Radium-223 Dichloride for Advanced Renal Cell Cancer with Bone Metastasis (RadiCal) Details The RadiCaL trial is comparing the effectiveness of cabozantinib alone versus cabozantinib combined with radium-223 in metastatic renal cell cancer patients. This phase II trial investigates if the addition of radium-223 to the standard treatment, cabozantinib, improves outcomes in patients with bone metastases. Radium-223 is a radioactive drug that can target cancer cells directly while minimizin...
The Benefit to Radium-223 Added to Cabozantinib for Patients With Renal Cell Carcinoma With Bone Metastasis, RadiCaL - Rana McKay Details Rana McKay joins Alicia Morgans to discuss the RadiCaL trial, a study looking at metastatic kidney cancer and the use of radium in that population. The trial is a phase II trial, taking patients with renal cell carcinoma (RCC) with bone metastases and randomizing them 1:1 to receive radium with cabozantinib versus cabozantinib alone. The primary endpoint of RadiCaL is a reduction in symptomatic sk...
The Alliance Trial A031801 - RadiCal a Trial of Radium-223 in Patients with Renal Cell Carcinoma, - Rana McKay Details Potentially practice-changing study sponsored by the National Cancer Institute — A discussion with Rana McKay, MD, principal investigator. Radium-223 (223Ra) is an alpha particle-emitting radioactive agent that received Federal Drug Administration (FDA) approval in 2013 to treat patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic diseas...